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Abstract: 
Topical preparations of Anemopsis californica have been used by Native American tribes in the 
southwestern United States and northern Mexico to treat inflammation and infections. We report 
results of bioassay-guided isolation conducted on a sample of A. californica roots. The furofuran 
lignans sesamin (1) and asarinin (2) were isolated and shown to have MIC values ranging from 
23 to 395 µM against five different species of environmental nontuberculous mycobacteria. 
These findings are significant given that these bacteria can cause skin, pulmonary, and lymphatic 
infections. Crude A. californica extracts were analyzed by liquid chromatography-mass 
spectrometry, and it was determined that sesamin and asarinin were extracted at relatively high 
levels from the roots (1.7–3.1 g/kg and 1.1–1.7 g/kg, respectively), but at lower levels from the 
leaves (0.13 g/kg for both compounds). Our findings suggest that the majority of activity of 
crude A. californica root extracts against nontuberculous mycobacteria can be attributed to the 
presence of sesamin and asarinin. This paper is the first to report the isolation of these 
compounds from a member of the Saururaceae family, and the first to describe their activity 
against nontuberculous mycobacteria. 
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A new arsenal of antibiotics is needed to address two problems involving the treatment of 
bacterial infections: the emergence of drug-resistance and the existence of bacteria that are 
innately resistant to most antibiotics. A promising source for new antibacterial compounds is the 
natural products produced by plants, bacteria, and fungi. It is estimated that 25 to 50 percent of 
anti-infective agents come from these natural sources [1]. This study focuses on the plant 
Anemopsis californica (Nutt.) Hook. & Arn. (Saururaceae) as a source of antimicrobial 
compounds. A. californica, commonly known as “yerba mansa”, is native to the southwestern 
United States and northern Mexico, and its roots, leaves, and stems have been used medicinally 
by many Native American tribes [2–5]. Despite an historical and modern precedent for the use of 
this plant to treat infection, only a few studies have focused on the chemicals responsible for its 
anti-infective properties [6,7]. The chemical compounds identified from A. californica thus far 
are exclusively from the volatile oils of the leaves and roots [8, 9]. Volatile oil extracts from A. 
californica have been shown to inhibit the growth of endometrial, cervical, colon, and breast 
cancer cells in vitro [8, 9], and demonstrated antimicrobial activity against Staphylococcus 
aureus, Streptococcus pneumoniae, and Geotrichim candidum [6]. Additionally, ethanol and 
ethyl acetate extracts of various parts of A. californica were shown to inhibit the growth of colon 
and breast cancer cells, and aqueous A. californica extracts inhibited cell migration and 
metastasis [10, 11]. These studies did not indicate which chemical constituents were responsible 
for the observed effects. 
 
There are currently no reports of the identities of nonvolatile compounds present in A. 
californica roots and leaves. This is a significant gap in the literature, given that the traditional 
mode of application of A. californica is a whole plant poultice or decoction. For example, the 
Shoshoni tribe of Nevada applied boiled and mashed A. californica roots to areas of 
inflammation and infections [2]. The Pima tribe of Arizona and New Mexico and the Mahuna 
and Chumash tribes of California used a decoction of leaves and roots to treat wounds [3,4,12], 
and the Nevada Paiute and the California Costanoan tribes used decoctions of A. californica 
roots or leaves to treat pain [2, 5]. The ethnobotanical precedent for application of A. californica 
to treat infections encouraged us to screen extracts from this plant for activity against pathogenic 
microorganisms. Activity of crude A. californica extracts was noted against several species of 
nontuberculousmycobacteria. These findingswere deemed significant, given the clinical 
relevance of these organisms. Nontuberculous mycobacteria are commonly found in soils, 
natural waters, and engineered water systems, including household plumbing [13, 14], and can 
cause pulmonary, skin, and lymph node infections [15]. The resultant chronic respiratory or soft 
tissue infections require long-term antibiotic treatment that can have serious side effects [16]. 
Current estimates report a total number of over 16000 cases in the United States of 
nontuberculosismycobacterial disease per year with a total cost of over $425 million [17]. The 
objective of this research was to identify compounds from A. californica with a potential for the 
treatment of nontuberculousmycobacterial infections. In addition, we sought to provide insight 
into the scientific basis for the ethnobotanical use of A. californica to treat bacterial infections. 
 
Results and Discussion 
 
Bioactivity-guided fractionation of A. californica resulted in the isolation of two compounds, 
sesamin (1) [18] and its C-7 epimer, asarinin (2) (Fig. 1). Sesamin was a white solid with an 
HRESIMS m/z of 355.1175 (calcd. for C20H19O6 [M + H]+ m/z 355.1176, [α]D25 = + 104, c = 
0.0125 g/100 mL, methanol). Asarinin, also called episesamin or isosesamin, was a white solid 
with an HRESIMS m/z of 355.1167 (calcd. for C20H19O6 [M + H]+ m/z 
355.1176, [α]D 25 = + 144, c = 0.0125 g/100 mL, methanol). The 1H and 13C NMR of both 
sesamin and asarinin were in agreement with literature values [19]. NMR data are included as 
Supporting Information (Table 1S, Figs. 1S–4S, Supporting Information). Although sesamin and 
asarinin are both known compounds, this is the first report of their presence in a member of the 
Saururaceae plant family. Sesamin was first isolated from sesame seed oil [20–22], while 
asarininwas first isolated from prickly ash bark [23]. Both sesamin and asarinin have been shown 
to act as insecticidal synergists with pyrethrins [21, 22]. Previous studies have shown that 
sesamin has moderate activity against Staphylococcus aureus and no activity against Escherichia 
coli [24]. In addition, asarinin was shown to be moderately active against S. aureus and Bacillus 





Figure 1. Structures of furofuran lignans sesamin (1) and asarinin (2) isolated from A. 
californica. 
 
Sesamin and asarinin demonstrated a range of antimicrobial activities (8 to 140 μg/mL or 22.6 
μM to 395 μM) against the five different species of Mycobacterium that were evaluated (Table 
1). This is the first report of activity of sesamin and asarinin against nontuberculous 
mycobacteria, although both sesamin and asarinin have been shown to lack activity against 
Mycobacterium tuberculosis [27]. These results are not surprising, given that members of the M. 
tuberculosis complex do not share the same susceptibilities to antimycobacterial antibiotics with 
the nontuberculous mycobacteria [16]. 
 
Crude A. californica extracts were tested against representative Mycobacterium species (Table 
1). Samples 1 and 3 (root extracts) demonstrated MIC values ranging from 125 to > 250 μg/mL, 
while sample 2 (aerial extract) demonstrated weak or no inhibition (MIC > 250 μg/mL). These 
differences in activity were likely due to the higher levels of sesamin and asarinin present in the 
roots as compared to the leaves (Table 2). 
 
The root extracts (samples 1 and 3) were significantly less active compared to the pure 
compounds. However, these extracts are crude mixtures, and sesamin and asarinin constituted 
only a fraction of their content (Table 2). Accounting for this difference, it appeared that the 
antimycobacterial activity of the crude extracts could be largely attributed to the presence of 
sesamin and asarinin. For example, sample 1, a root extract of A. californica, demonstrated an 
MIC of 125 μg/mL against Mycobacterium smegmatis (Table 1). Sample 1 contained 8.8 ± 1.0% 
sesamin and 4.7 ± 0.4% asarinin (Table 2); thus, the MIC of 125 μg/mL (expressed as mass of 
crude extract/volume media) is equivalent to 16.8 μg/mL (expressed as mass of sesamin and 
asarinin combined per volume of media). This value is within the range of the reported 
MICs for sesamin and asarinin alone against M. smegmatis (8 and 35 μg/mL, respectively). 
 
Table 1. Minimum inhibitory concentrations (MIC) of the crude extracts of A. californica, 
sesamin, and asarinin against Mycobacterium species. 










Sample 1a  125  > 250  > 250  250  125 
Sample 2a  > 250  > 250  > 250  > 250 > 250 
Sample 
3b  
125  > 250  250  > 250  > 250 
Sesamin  8  > 130  65  13  8 
Asarinin  35  > 140  140  35  35 
Rifampinc  25  0.8  0.15  0.8  2 
a Samples 1 and 2 are for root and aerial extracts, respectively, from the same A. californica 
plant. b Sample 3 represents a large batch root extract that was subjected to bioactivity-directed 
fractionation, resulting in the isolation of sesamin and asarinin. c The antibiotic rifampin is 
included as a positive control. The negative control (vehicle, 2% DMSO) caused no significant 
growth inhibition 







concentrationa  yieldb 
(ppt) ± SD 









Sample 1  root  3.1 ± 0.3  8.8 ± 1.0  1.7 ± 0.1  4.7 ± 0.4 
Sample 2  leaf/stem  0.13 ± 0.02  0.95 ± 0.14  0.13 ± 0.02  0.9 ± 0.2 
Sample 3  root  1.7 ± 0.2  8.8 ± 0.9  1.1 ± 0.1  5.9 ± 0.2 
a Concentrations were determined by LC‑MS analysis of extracts prepared from the relevant 
plant parts. Standard deviations are for triplicate analyses of the same extract. The extract 
concentration was calculated based on linear regression analysis of 6-point calibration curves of 
the peak area versus the concentration with a slope (m) = 587881 ± 4628, intercept (b) = − 20512 
± 10554, and R2 = 0.9998 for sesamin, and a slope (m) = 647726 ± 16450, intercept (b) = − 
15594 ± 37516, and R2 = 0.9974 for asarinin. Extracts were diluted so that the concentrations 
tested fell within the linear range of the calibration curve.  
b The yield is reported as parts per thousand or mass of pure compound (g) per mass of original 
plant material (kg).  
c The % in extract is reported as mass (g) of sesamin or asarinin per mass of solid extract (g) × 
100. The % in extract values are provided for the purpose of comparison with biological data 
In conclusion, the results of the quantitative analysis suggest that the majority of activity of A. 
californica root extracts against nontuberculous mycobacteria can be attributed to the presence of  
relatively high levels of sesamin and asarinin. Importantly, the presence of antimycobacterial 
compounds in A. californica roots supports the traditional use of this plant as a treatment for 
infection, although follow-up studies would be necessary to evaluate the in vivo relevance of 
these findings. The higher levels of sesamin and asarinin in the roots than in the leaves suggest 
that the root extracts would be more effective than the leaf extracts for the treatment of 
mycobacterial infections.  
 




Cultivated A. californica plant material was obtained from two sites, Horizon Herbs in Williams, 
OR (42°12′ 17.21′′N, 123°19′ 34.61′′W; voucher number NCU592735, identified by Richard A. 
Cech) and Apache Creek Ranch in Santa Fe, NM (35°35′ 56.40′′N, 105°50′ 27.22′′W; voucher 
number NCU602027, identified by Amy Brown). Vouchers are retained at the University of 
North Carolina Herbarium. Harvested plant material was separated into three different portions, a 
root sample (sample #1, 9.8 g dry weight), a leaf/stem sample from the same plant (sample #2, 
7.5 g dry weight, both harvested from Horizon Herbs in April 2010), and a large batch of 
roots/rhizomes to facilitate isolation work (sample #3, 520 g dryweight, harvested from Apache 
Creek Ranch in November 2010). All plant material was air-dried prior to extraction. 
 
Extraction and liquid chromatography-mass spectrometry 
 
Three batches of A. californica plant material were cut and ground, and then macerated in 
methanol for 24 hours. The marc for each extract was subsequently soaked in methanol a total of 
three times, and the methanol was decanted and combined. The methanol extracts were 
evaporated to dryness with a rotary evaporator and subjected to liquid-liquid partitioning using 
published methods [28]. Briefly, the methanol extract was defatted by partitioning between a 1:1 
ratio of hexane to methanol, and the latter fraction was then dried and further partitioned between 
4:1:5 of chloroform:methanol:water. The chloroform fraction was evaporated to dryness and its 
antimicrobial activity was tested using a broth microdilution assay. The yields from the 
chloroform fraction of samples 1, 2, and 3 were 343 mg, 104 mg, and 10 g, respectively. 
 
For the isolation of the active compounds, the chloroformextract (10 g, sample #3, roots and 
rhizomes) was subjected to two stages of normal-phase chromatography on a CombiFlash® Rf 
ISCO using 120 g RediSep Rf Gold® silica columns (20–40 μm particle size, Teledyne ISCO). 
The first stage of normal-phase chromatography was performed with a 
hexane/chloroform/methanol gradient on silica gel (eluent chloroform and methanol, flow rate 18 
mL/min) and the eluate was pooled into 12 fractions. Fraction VI (360–450mL, 645 mg) was 
subjected to a second stage of separation with a hexane/acetone/methanol gradient on silica gel 
(eluent acetone and methanol, flow rate 18mL/min) and pooled into 10 fractions. Fraction V 
(250–320mL, 420mg), the active fraction, was then subjected to further purification with two 
successive stages of isocratic separation with reversed-phase preparative HPLC on a C18 column 
(Phenomenex, Gemini-NX, 5 μm, 250 × 21.2 mm, flow rate 21mL/min). The first stage of 
reversedphase separation employed a 50:50 acetonitrile :water isocratic mobile phase 
composition, and the eluate was pooled into 5 fractions. Fractions II and III from this separation 
(200–300 mL and 320–400 mL, 75mg and 80 mg, respectively) were then combined and 
subjected to a second reversed-phase separation with an isocratic mobile phase composition of 
75:25 methanol:water. Sesamin (1) (0.012% yield, 60mg, 98.3% purity) was eluted at 15 min 
and asarinin (2) (0.0096% yield, 60mg, 98.5% purity) was eluted at 16.5 min. 
Test bacteria, chemicals, biochemicals, and minimal inhibitory concentration 
 
Mycobacterium marinum (ATCC strain 927), M. smegmatis strain mc2 155 (ATCC strain 
700084), Mycobacterium abscessus strain AAy-P‑1, Mycobacterium chelonae strain EO‑P‑1, 
Mycobacterium intracellulare strain TMC 1406T (ATCC 13950), and Mycobacterium avium 
strain A5 [29,30] were grown in Middlebrook 7H9 broth medium containing 0.5% (v/v) glycerol 
and 10% (v/v) oleic acid-albumin with aeration (120 rpm) for 7 days at 37°C or 30°C 
(only M. marinum). The minimal inhibitory concentration (MIC) of each fraction or compound 
was measured by broth microdilution with a starting inoculum of 0.5–1.0 × 105 CFU/mL [30, 
31]. The plates were incubated for 4 days at 37°C or 30°C (M. marinum only) and the turbidity 
was measured (absorbance 580 nm). Extracts were tested over a concentration range of 0.12 to 
250 μg/mL by twofold dilutions in the presence of a constant DMSO concentration (2%). The 
MIC was defined as the lowest concentration completely inhibiting bacterial growth. Rifampin 
(Sigma, purity ≥ 97%) served as the control. 
Quantitative analysis 
 
Sesamin and asarinin were identified in crude A. californica extracts by matching retention time 
and fragmentation patterns with those of the isolated standard compounds. The concentrations of 
these compounds were then measured using selective reaction monitoring (SRM) on a triple 
quadrupole mass spectrometer (TSQ Access; Thermo Scientific,) with an electrospray ionization 
source in the positive ion mode. Transitions of 337.1 to 203.1 and 337.1 to 289.2 were employed 
for the isomeric compounds. The mass spectrometer was coupled to a reversed-phase 
highperformance liquid chromatograph (HPLC) (Agilent HP1200) with a pentafluorophenyl 
(PFP) column (5 μm, 150 × 4.6 mm; Phenomenex). An acetonitrile (1% formic acid):water (1% 
formic acid) gradient was employed at 1.0mL/min with HPLC grade solvents. A calibration 
curve (concentration range of 0.05 to 5.0 μg/mL) of concentration versus average peak area for 
triplicate injections was employed for quantitative analysis. The extracts were diluted so that 




NMR spectroscopic data, 1H‑NMR spectra, and 13C‑NMR spectra for sesamin and asarinin 
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